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A rare case of the upper extremity diffuse large B-cellLOGO
lymphoma
mimicking soft tissue sarcoma in an elderly patient
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Abstract: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma,
with about 30% of new cases presenting with extranodal disease. Lesions originating from soft tissues of
the upper extremities are extremely rare and may mimic other malignancies like sarcoma. We present a case
of an elderly patient with right upper extremity (RUE) mass which was proven to be DLBCL instead of
sarcoma. We emphasize the increasing need for investigating new therapeutic options for patients of extreme
age and/or with underlying heart disease.
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Introduction

Case presentation

Diffuse large B-cell lymphoma (DLBCL) is the most
common amongst non-Hodgkin lymphomas, accounting
for approximately 30% of all cases. Most of the times,
disease primarily occurs in the lymph nodes, but extranodal
involvement is not uncommon. About 30% of DLBCL cases
present with disease outside the lymph nodes, which may
incur different clinicopathologic features and prognosis for
these patients (1-3). Cases involving soft tissues often mimic
other entities like sarcoma. Treatment options remain the
same for both nodal and extranodal DLBCL, with the first
choice being chemoimmunotherapy including anthracyclines
(4-10). Age and preexisting medical conditions are the
main limiting factors in planning the treatment. Regimens
including alternatives to the cardiotoxic therapies have
been investigated. Phases I and II studies incorporating the
liposomal form of doxorubicin showed promising results for
the patients who would otherwise be deprived of the most
effective therapies (11-13). We present a case of an elderly
patient with right upper extremity (RUE) mass which was
proven to be DLBCL instead of sarcoma. We emphasize the
increasing need for investigating new therapeutic options for
patients of extreme age and/or with underlying heart disease.

The patient was a 90-year-old male who was referred for
evaluation of a RUE mass. The patient and family reported
decreased appetite and fatigue, as well as weight loss of
about 20 pounds in the preceding 6 months. Patient’s
past medical history was significant for hypertension,
cerebrovascular accident with residual expressive aphasia
and benign prostate hyperplasia. Located in the anterior
aspect of the right upper arm, just above the antecubital
fossa, the mass was described as a large violaceous fleshy
tumor of approximately 10 cm × 7 cm in size. Not tender,
with intact skin, the lesion was associated with mild
RUE edema. Three months earlier patient was evaluated
by surgery for the same lesion. The ultrasound study
of the lesion showed heterogeneous mass or collection
of about 7.8 cm × 4.6 cm × 5.2 cm in size, MRI study
showed a mass of 10.1 cm × 5.3 cm × 6.8 cm within the
musculature of the right arm, as well as additional 1.4 cm
× 1.9 cm × 2.5 cm focus surrounding the brachioradialis
neurovascular bundle, which was in contiguity with the
larger mass. The radiological picture was highly suggestive
of soft tissue sarcoma or other malignant neoplasm. At
this time, patient was reluctant to pursue further work up
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Figure 1 Immunohistochemical studies of the specimen from core biopsies of the right upper extremity mass. The specimens were positive
for CD20, Pax5, BCL2, and Ki67. The magnifications are 20× for the figures.

and was noncompliant with follow up. After presenting to
oncology the patient was referred for biopsy of the mass,
which again he did not pursue. Two months later the
patient was admitted to the hospital; the mass was then
fungating and ulcerated, with purulent discharge. Patient
was managed for wound infection. MRI of the RUE showed
interval growth and ulceration of the mass lesion measuring
15.4 cm × 4.9 cm × 7.7 cm, encasing the brachial vessels, as
well as possible extension into the axilla with involvement
of the brachial plexus. Biopsy was performed during the
hospital stay and the H&E sections revealed multiple cores
with diffuse proliferation of atypical lymphocytes with focal
crush/degeneration artifacts and areas of tumor necrosis.
Scattered entrapped skeletal muscle fibers were seen in focal
areas. The atypical lymphocytes were large in size and had
moderate cytoplasm, round to irregular nuclear contour,
some indented, clumped to fine vesicular chromatin and
some with one to multiple nucleoli. Mitosis/apoptosis were
easily seen. Scattered small reactive lymphocytes were
seen in the background. The atypical lymphocytes were
diffusely positive for CD20, Pax5 and BCL2 (Figure 1),
while they were negative for CD3, CD5, CD10, BCL6,
BCL1, MUM-1, CD30, CD56, CD34, pancytokeratin
(AE1/AE3), MyoD1, and HMB-45. CD3 and CD5
highlighted background reactive small T-cells. Ki-67
stain showed high nuclear proliferation index (85–90% of
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neoplastic cells were positive). The findings were consistent
with DLBCL, activated B-cell like (ABC). Staging work
up was performed. CT of the chest, abdomen and pelvis
did not reveal any changes suspicious for disease spread,
however bone marrow biopsy showed minimal involvement
with B-cell lymphoma. Upon presentation patient had
hemoglobin level 12.6 g/dL, white blood cell count
(WBC) of 6,800/mm3 with predominance of neutrophils
(88%) and a normal platelet count (207 K/mm 3 ).
LDH was 337 U/L. Echocardiography revealed left
ventricular ejection fraction (LVEF) of 45%. His Eastern
Cooperative Oncology Group (ECOG) performance status
was 2. After extensive discussion with the patient and the
family, chemotherapy with R-CHOP regimen (rituximab,
cyclophosphamide, doxorubicin, vincristine and prednisone)
was advised with modifications. Due to decreased LVEF
and advanced age the regimen included the pegylated
liposomal formulation of doxorubicin given at the dose of
30 mg/m2, based on regimens cited in the literature (11,12).
The remaining medications were administered at standard
doses. After the first cycle of chemotherapy there was some
noticeable improvement in the extent of the RUE lesion.
However, when blood counts decreased, the patient’s overall
status started to deteriorate and his activity and oral intake
significantly declined. The patient and the family desired
for comfort and supportive care only. Therefore the patient
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was discharged to a hospice facility.
Discussion
The analysis of the Surveillance, Epidemiology End
Results Database between 2004 and 2009 identified 31.6%
of DLBCL cases presenting with primary extranodal
involvement. Gastrointestinal tract was the most common
site (10.7%), followed by head and neck (4.3%), with skin
and soft tissue representing 3.3% of cases. In the same
population study extranodal presentation is related with
older age, early presentation and, depending on location,
incurs different prognosis. Better outcomes were observed
with head and neck involvement, whereas worse outcomes
with GI tract, liver, pancreas and lung involvement. In a
single institution report combined with meta-analysis of
published cases and case series (2), authors included a total
of 83 patients with primary extranodal lymphoma. The
most common subtype was DLBCL. Authors observed
a trend towards inferior outcomes in DLBCL compared
to indolent lymphomas and increased chance of CNS
relapse. Because of the limitations of the data (lacking
information about prognostic factors) and small sample
size, no conclusion about best treatment options could
have been made. In another single institution study of 262
patients, authors compared outcomes of the nodal and
extranodal DLBCL before and after introduction of the
immunotherapy with rituximab to standard treatment (3).
Authors point to the fact that the group with the greater
benefit from the addition of rituximab was the primary
nodal involvement DLBCL, emphasizing potential
clinicobiological differences between the two groups, like
IPI (international Prognostic Index) scores at presentation
or single gene alterations (3,14). Cases involving soft
tissues often mimic other entities like sarcomas, malignant
melanoma, or metastatic carcinomas (14-22). In our case,
the initial presentation, imaging studies, as well as fast
growth of the lesion raised strong suspicion of a soft tissue
sarcoma. Our patient presented with high risk disease.
The first line therapy for this type of high risk DLBCL
recommended by the National Comprehensive Cancer
Network is R-CHOP or dose-adjusted R-EPOCH
(4-8,23,24). However, about 50% of patients are above 60
years old at the time of diagnosis. Therefore, regimens
including alternatives to the cardiotoxic therapies have been
investigated. Phase I and II studies incorporating liposomal
form of doxorubicin showed promising results (11-13,23,24).
The pegylated form of doxorubicin compared to traditional
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doxorubicin has longer half-life, reduced volume of
distribution, as well preferential distribution into neoplastic
tissues, at the same time carrying the benefit of lower
toxicity and improved therapeutic activity (12,13). Other
measures which might be implemented in order to reduce
cardiac toxicity are to treat the patient with conventional
doxorubicin in continuous infusion over 72–96 h (25) and
to use dexrazoxane (26). The use of the latter however,
raised concerns of increased myelotoxicity and possible
tumor protective effect. Its administration in the setting
of chemotherapy induced cardiomyopathy is currently
limited to women with breast cancer, who had received a
cumulative dose of doxorubicine of 300 mg/m2. Regimen
with decreased doses of cyclophosphomide, doxorubicin,
vincristine and prednisone (R-miniCHOP) is another
possibility for frail patients older than 80 years old (27). In
the patient presented in our report, the regimen containing
liposomal doxorubicin was a reasonable choice in attempt to
control an advanced, high-risk disease in an elderly patient
with deteriorating performance status and decreased cardiac
function. However, all of the above therapies carry a burden
of significant toxicities and there is an increasing need for
novel targeted agents for the treatment of the population of
elderly and frail patients (28-34).
Conclusions
This patient represents an extremely rare case of RUE
lymphoma, mimicking soft tissue sarcoma. This elderly
patient with poor performance status and decreased cardiac
function had limited treatment options. Novel targeted
agents should be explored for this population of patients
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